Gabriel Fenteany, Ph.D.

Biological Research Centre of the Hungarian Academy of Sciences, Temesvári krt. 62, Szeged, 6726, Hungary
fenteany@brc.hu; https://www.linkedin.com/in/fenteany; +36-70-599-685, +36-70-359-3606
Citizenship: Dual USA and Hungary/EU

EDUCATION

Ph.D., Biochemistry, 1997, Harvard University, Cambridge, Massachusetts (thesis title: Lactacystin, Proteasome Function and Cell Morphology; advisors: Prof. Stuart L. Schreiber and Prof. Elias J. Corey)

M.A., Biochemistry and Molecular Biology, 1992, University of California, Santa Barbara (thesis title: Antibiotic Inhibitors of Protein Synthesis: Relative Efficacy in Larvae of *Haliotis rufescens* (Gastropod Mollusc) and Effects on Larval Settling Behavior; advisor: Prof. Daniel E. Morse)

B.A., Biochemistry, Aquatic Biology, 1990, University of California, Santa Barbara

***Licence* (B.S. equivalent)**, Biology, 1989, Université de Franche-Comté, France (as foreign exchange student from Reed College, Portland, Oregon, 1985 – 1989)

RELEVANT PROFESSIONAL EXPERIENCE

RESEARCH

Senior Research Scientist and Group Leader, Institute of Genetics, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, Hungary, 2017 – present

Senior Research Scientist/Research and Grants Advisor, Research Administration and Data Sciences Research Center, New York City Health and Hospitals, New York and New York University Medical Center, 2015 – 2017

Senior Research Scientist, Division of Endocrinology, New York City Health and Hospitals/Woodhull and New York University Medical Center, New York, 2015 – 2017

Faculty of the Cell Biology Graduate Program, University of Connecticut, Storrs, 2008 – 2015

Faculty Co-Director, High-Throughput Screening Facility, University of Connecticut, Storrs, 2008 – 2015

Faculty of the Structural Biology Partnership, University of Connecticut, Storrs, 2008 – 2015

Associate Professor of Chemistry, University of Connecticut, Storrs, 2006 – 2015

Assistant Professor of Chemistry, University of Illinois, Chicago, 2000 – 2006

Life Sciences Research Foundation Postdoctoral Fellow, Harvard Medical School, Boston, Massachusetts, 1997 – 2000

TEACHING

Associate Professor of Chemistry, University of Connecticut, Storrs, 2006 – 2015

- Taught seven semesters of Organic Chemistry I and II (undergraduate classes)
- Taught six semesters of Biological Chemistry (graduate class)
- Ran or taught various other seminar and lab research courses

Assistant Professor of Chemistry, University of Illinois, Chicago, 2000 – 2006

- Taught four semesters of Biochemistry I (undergraduate class)
- Taught six semesters of Chemical Biology and Bioorganic Chemistry (graduate class)
- Ran or taught various other seminar and lab research courses

Graduate Teaching Fellow, Harvard University, Cambridge, Massachusetts, 1994 – 1996

Graduate Teaching Assistant, University of California, Santa Barbara, 1991

WEB DEVELOPMENT AND CONTENT CREATION

Creator and Maintainer, The Virtual Library of Biochemistry, Molecular Biology and Cell Biology: http://biochemweb.net, 1999 – present

Creator and Maintainer, Websites for the Divisions of Experimental Medicine and Hematology, Brigham and Women's Hospital, Harvard Medical School, 1998 – 2000

NARRATIVE

I have years of experience as an independent professional scientist, with a strong record of influential publications, presentations, and grant funding. I am presently a senior research scientist and group leader at the Biological Research Centre of the Hungarian Academy of Sciences where my research is focused on chemical biology and probing and controlling DNA repair and damage tolerance pathways. I was formerly a university professor in chemistry and then a hospital-based biomedical researcher, both in the United States. May main focus of research has been chemical biology, organic chemistry, biochemistry, and cell biology, particularly the discovery of novel modulators of basic biological processes of medical significance, the unbiased isolation of their molecular targets, the characterization of protein-small molecule interactions, and the dissection of the pathways controlling cell motility, with an interest in collective cell migration (the understudied but widespread phenomenon whereby cells move together as groups). My group made major contributions to the discovery of novel anti-migratory and pro-migratory agents and to the understanding of the functions and roles of their protein targets in cancer progression, metastasis, wound healing, and related processes. I have mentored 8 post-doctoral fellows, 13 Ph.D. students, 6 M.S. students, 18 undergraduate researchers, two technicians, and two high school scholars. I have been the principal investigator on major grants from the National Institutes of Health, the American Cancer Society, and other funding agencies and foundations.

GRANTS

R01GM077622, Fenteany, G. (PI), 06/01/2006 – 05/31/2013
National Institutes of Health (NIGMS)
Mechanism of Action of New Inhibitors of Cell Migration — Role: PI — Amount: $1,295,000

R01GM077622 Supplement, Fenteany, G. (PI), 09/11/2009 – 08/31/2012
National Institutes of Health (NIGMS)
Mechanism of Action of New Inhibitors of Cell Migration — Role: PI — Amount: $200,451

R01GM077622 Supplement, Fenteany, G. (PI), 01/01/2008 – 05/31/2011
National Institutes of Health (NIGMS)
Research Supplements to Promote Diversity in Health-Related Research — Role: PI — Amount: $175,252

Summer Undergraduate Research Fellowship, Lincoln, S.T. (Awardee), 06/2011 – 08/2011
University of Connecticut — Role: PI — Amount: $3,990

Summer Undergraduate Research Fellowship, Minutolo, N. (Awardee), 06/2011 – 08/2011
University of Connecticut — Role: Co-PI with David Knecht — Amount: $4,000

University of Connecticut Major Research Equipment Award, Hadden, K. (PI), 10/22/2010
UConn High-Throughput Screening Center — Role: Key Personnel — Amount: $221,530

Summer Undergraduate Research Fellowship, Heyse, S.A. (Awardee), 06/2010 – 08/2010
University of Connecticut — Role: PI — Amount: $2,500

University of Connecticut Intermediate Research Equipment Award, Yao, X. (PI), 12/11/2009
Nano Liquid Chromatography System — Role: Key Personnel — Amount: $99,000

UCHC/Storrs and Regional Campus Incentive Grant, Wright, D. (PI), 09/01/2008 – 08/31/2009
A High Throughput Screen to Identify Novel Anti-Cancer Agents — Role: Co-PI — Amount: $50,000

Summer Undergraduate Research Fellowship, Morse, P.D. (Awardee), 06/2009 – 08/2009
University of Connecticut — Role: PI — Amount: $3,000

Partnership for Excellence in Structural Biology Research Fellowship, 01/01/2008 – 05/31/2008
University of Connecticut Partnership for Excellence in Structural Biology
Fenteany, G. (PI), Alexandrescu, A.T. (Co-PI) — Role: PI — Amount: $12,735

Partnership for Excellence in Structural Biology Research Fellowship, 08/01/2008 – 12/31/2007
University of Connecticut Partnership for Excellence in Structural Biology
Gascón, J.A. (PI), Fenteany, G. (Co-PI) — Role: Co-PI — Amount: $12,735

Summer Undergraduate Research Fellowship, Drozdowicz, L.B. (Awardee), 06/2007 – 08/2007
University of Connecticut — Role: PI — Amount: $3,000

0722948 (Major Research Instrumentation), Knecht, D.A. (PI), 09/01/2007
National Science Foundation

Acquisition of a Confocal Live Cell Imaging System Role: Sr. Personnel Amount: $367,305

RSG-02-250-01-DDC, Fenteany, G. (PI), 07/01/2002 – 06/30/2006
American Cancer Society
Probes to Study and Control Cell Motility and Morphogenesis Role: PI Amount: $650,000

R21CA95177, Fenteany, G. (PI), 04/01/2002 – 03/31/2003
National Institutes of Health (NCI)
Discovery of Drug Targets Controlling Cell Motility Role: PI Amount: $148,573

Campus Research Board Grant, Fenteany, G. (PI), 07/01/2001 – 06/30/2002
University of Illinois
Small Organic Molecules to Study and Control Cell Motility Role: PI Amount: $15,000

0091994 (Major Research Instrumentation), Keiderling, T.A (PI), 02/15/2001
National Science Foundation
Purchase of a Departmental Stopped-Flow Equipped Circular Dichroism Spectrometer
Role: Co-PI Amount: $112,572

PEER-REVIEWED PUBLICATIONS

Fenteany, G., Inoue, T., Bahtiyar, G., Sacerdote, A. Association of vitamin D repletion with normalization of elevated serum 17-OH progesterone. *J. Med. Case Rep.*, 2017, 3:22.

Powell, D., Inoue, T., Bahtiyar, G., Fenteany, G, Sacerdote, A. Treatment of nonclassic 11-hydroxylase deficiency with Ashwagandha root. *Case Rep. Endocrinol*. 2017, 2017:Article ID 1869560.

Eddy, N.A. Fenteany, G. Model studies directed to the synthesis of cucurbitacin I C/D rings. *Tetrahedron Lett.* 2015, 56:5079-5081.

Magpusao, A.N., Omolloh, G., Johnson, J., Gascón, J., Peczuh, M.W., Fenteany, G. Cardiac glycoside activities link Na^+/K^+ ATPase ion-transport to breast cancer cell migration via correlative SAR. *ACS Chem. Biol.* 2015, 10:561–569.

Eddy, N.A., Richardson, J.J., Fenteany, G. The effect of Lewis acids on the cycloaddition of 3,3,6-trimethylcyclohex-5-ene-1,2,4-trione: Hydrogen transfer versus cycloaddition with cyclopentadiene. *Eur. J. Org. Chem.* 2013, 23:5041–5044.

Clark, A.G., Sider, J.R., Verbrugghe, K., Fenteany, G., von Dassow, G., Bement, W.M. Identification of small molecule inhibitors of cytokinesis and single cell wound repair. *Cytoskeleton* 2012, 69:1010–1020.

Eddy, N.A., Kelly, C.B., Mercadante, M.A., Leadbeater, N.E., Fenteany, G. Access to dienophilic ene-triketone synthons by oxidation of diketones with an oxoammonium salt. *Org. Lett.* 2012, 14:498–501.

Ren, G., Baritaki, S., Marathe, H., Feng, J., Park, S., Beach, S., Bazeley, P.S., Beshir, A.B., Fenteany, G., Mehra, R., Daignault, S., Al Mulla, F., Keller, E., Bonavida, B., de la Serna, I., Yeung, K.C. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. *Cancer Res.* 2012, 72:3091–3104.

Rudnitskaya, A.N., Eddy, N.A., Fenteany, G., Gascón, J.A. Recognition and reactivity in the binding between Raf kinase inhibitor protein and its small-molecule inhibitor locostatin. *J. Phys. Chem. B.* 2012, 116:10176–10181.

Beshir, A.B., Argueta, C.E., Menikarachchi, L.C., Gascón, J.A., Fenteany, G. Locostatin disrupts association of Raf kinase inhibitor protein with binding proteins by modifying a conserved histidine residue in the ligand-binding pocket. *Forum Immunopath. Dis. Ther.* 2011, 2:47–5

Eddy, N.A., Morse, P.D., Morton, M.D., Fenteany, G. Synthesis of oxazolidinone and tosyl enamines by tertiary amine catalysis. *Synlett* 2011, 5:699–701.

Wang, Z., Castellano, S., Kinderman, S.S., Argueta, C.E., Beshir, A.B., Fenteany, G., Kwon, O. Diversity through a branched reaction pathway: Generation of a library of sixteen multicyclic scaffolds and identification of antimigratory agents. *Chem. Eur. J.* 2011, 17:649–654.

Beshir, A.B., Ren, G., Magpusao, A.N., Barone, L.M., Yeung, K.C., Fenteany, G. Raf kinase inhibitor protein suppresses nuclear factor-κB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. *Cancer Lett.* 2010, 299:137–149.

Kahsai, A.W., Zhu, S., Fenteany, G. G protein-coupled receptor kinase 2 activates radixin, regulating membrane protrusion and motility in epithelial cells. *Biochim. Biophys. Acta* 2010, 1803:300–310.

Knecht, D.A., LaFleur, R., Kahsai, A.W., Argueta, C.E., Beshir, A.B., Fenteany, G. Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics. *PLoS One* 2010, 5:e14039.

Magpusao, A.N., Desmond, R., Billings, K.J., Fenteany, G., Peczuh, M.W. Synthesis and evaluation of antimigratory and antiproliferative activities of lipid-linked [13]-macro-dilactones. *Bioorg. Med. Chem. Lett.* 2010, 20:5472–5476.

Ménoret, A., McAleer, J.P., Ngoi, S.-M., Ray, S., Eddy, N.A., Fenteany, G., Lee, S.-J., Rossi, R.J., Mukherji, B., Allen, D.L., Chakraborty, N.G., Vella, A.T. The oxazolidinone derivative locostatin induces cytokine appeasement. *J. Immunol.* 2009, 183:7489–7496.

Beshir, A.B., Guchhait, S.K., Gascon, J.A., Fenteany, G. Synthesis and structure–activity relationships of metal–ligand complexes that potently inhibit cell migration. *Bioorg. Med. Chem. Lett.* 2008, 18:498–504.

Kahsai, A.W., Cui, J., Kaniskan, H.Ü., Garner, P.P., Fenteany, G. Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site. *J. Biol. Chem.* 2008, 283:24534–24545.

Mc Henry, K.T., Montesano, R., Zhu, S., Beshir, A.B., Tang, H.H., Yeung, K.C., Fenteany, G. Raf kinase inhibitor protein positively regulates cell–substratum adhesion while negatively regulating cell–cell adhesion. *J. Cell. Biochem.* 2008, 103:972–985.

Farooqui, R., Zhu, S., Fenteany, G. Glycogen synthase kinase-3 acts upstream of ADP-ribosylation factor 6 and Rac1 to regulate epithelial cell migration. *Exp. Cell Res.* 2006, 312:1514–1525.

Kahsai, A.W., Zhu, S., Wardrop, D.J., Lane, W.S., Fenteany, G. Quinocarmycin analog DX-52-1 inhibits cell migration and targets radixin, disrupting interactions of radixin with actin and CD44. *Chem. Biol.* 2006, 13:973–983.

Stossel, T.P., Fenteany, G., Hartwig, J.H. Cell surface actin remodeling. *J. Cell Sci.* 2006, 119:3261–3264.

Farooqui, R., Fenteany, G. Multiple rows of cells behind an epithelial wound edge extend cryptic lamellipodia to collectively drive cell-sheet movement. *J. Cell Sci.* 2005, 118:51–63.

Zhu, S., Mc Henry, K.T., Lane, W.S., Fenteany, G. A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. *Chem. Biol.* 2005, 12:981–991.

Altan, Z.M., Fenteany, G. c-Jun N-terminal kinase regulates lamellipodial protrusion and cell sheet migration during epithelial wound closure by a gene expression-independent mechanism. *Biochem. Biophys. Res. Commun.* 2004, 322:56–67.

Fenteany, G., Glogauer, M. Cytoskeletal remodeling in leukocyte function. *Curr. Opin. Hematol.* 2004, 11:15–24.

Ankala, S.V., Fenteany, G. Aryl, alkyl bis-silyl ethers: Rapid access to monoprotected aryl alkyl and biaryl ethers. *Synlett* 2003, 6:825–828.

Fenteany, G., Zhu, S. Small-molecule inhibitors of actin dynamics and cell motility. *Curr. Topics Med. Chem.* 2003, 3:593–616.

Ankala, S.V., Fenteany, G. Selective deprotection of either aryl or alkyl silyl ethers from aryl, alkyl bis-silyl ethers. *Tetrahedron Lett.* 2002, 43:4729–4732.

Mc Henry, K.T., Ankala, S.V., Ghosh, A.K., Fenteany, G. A non-antibacterial oxazolidinone derivative that inhibits epithelial cell sheet migration. *ChemBioChem* 2002, 3:1105–1111.

Fenteany, G., Janmey, P.A., Stossel, T.P. Signaling pathways and cell mechanics involved in wound closure by epithelial cell sheets. *Curr. Biol.* 2000, 10:831–838.

Corey, E.J., Li, W.Z., Nagamitsu, T., Fenteany, G. The structural requirements for inhibition of proteasome function by the lactacystin-derived β-lactone and synthetic analogs. *Tetrahedron* 1999, 55:3305–3316.

Fenteany, G., Schreiber, S.L. Lactacystin, proteasome function, and cell fate. *J. Biol. Chem.* 1998, 273:8545–8548.

Degnan, B.M., Degnan, S.M., Fenteany, G., Morse, D.E. A Mox homeobox gene in the gastropod mollusc *Haliotis rufescens* is differentially expressed during larval morphogenesis and metamorphosis. *FEBS Lett.* 1997, 411:119–122.

Craiu, A., Gaczynska, M., Akopian, T., Gramm, C.F., Fenteany, G., Goldberg, A.L., Rock, K.L. Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. *J. Biol. Chem.* 1997, 272:13437–13445.

Fenteany, G., Schreiber, S.L. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. *Chem. Biol.* 1996, 3:905–912.

Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., Corey, E.J., Schreiber, S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. *Science* 1995, 268:726–731.

Fenteany, G., Standaert, R.F., Reichard, G.A., Corey, E.J., Schreiber, S.L. A Fenteany, G., Inoue, T., Bahtiyar, G., Sacerdote, A. Association of vitamin D repletion with normalization of elevated serum 17-OH progesterone. *J. Med. Case Rep.*, 2017, 3:22.

Powell, D., Inoue, T., Bahtiyar, G., Fenteany, G, Sacerdote, A. Treatment of nonclassic 11-hydroxylase deficiency with Ashwagandha root. *Case Rep. Endocrinol*. 2017, 2017:Article ID 1869560.

Eddy, N.A. Fenteany, G. Model studies directed to the synthesis of cucurbitacin I C/D rings. *Tetrahedron Lett.* 2015, 56:5079-5081.

Magpusao, A.N., Omolloh, G., Johnson, J., Gascón, J., Peczuh, M.W., Fenteany, G. Cardiac glycoside activities link Na^+/K^+ ATPase ion-transport to breast cancer cell migration via correlative SAR. *ACS Chem. Biol.* 2015, 10:561–569.

Eddy, N.A., Richardson, J.J., Fenteany, G. The effect of Lewis acids on the cycloaddition of 3,3,6-trimethylcyclohex-5-ene-1,2,4-trione: Hydrogen transfer versus cycloaddition with cyclopentadiene. *Eur. J. Org. Chem.* 2013, 23:5041–5044.

Clark, A.G., Sider, J.R., Verbrugghe, K., Fenteany, G., von Dassow, G., Bement, W.M. Identification of small molecule inhibitors of cytokinesis and single cell wound repair. *Cytoskeleton* 2012, 69:1010–1020.

Eddy, N.A., Kelly, C.B., Mercadante, M.A., Leadbeater, N.E., Fenteany, G. Access to dienophilic ene-triketone synthons by oxidation of diketones with an oxoammonium salt. *Org. Lett.* 2012, 14:498–501.

Ren, G., Baritaki, S., Marathe, H., Feng, J., Park, S., Beach, S., Bazeley, P.S., Beshir, A.B., Fenteany, G., Mehra, R., Daignault, S., Al Mulla, F., Keller, E., Bonavida, B., de la Serna, I., Yeung, K.C. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. *Cancer Res.* 2012, 72:3091–3104.

Rudnitskaya, A.N., Eddy, N.A., Fenteany, G., Gascón, J.A. Recognition and reactivity in the binding between Raf kinase inhibitor protein and its small-molecule inhibitor locostatin. *J. Phys. Chem. B.* 2012, 116:10176–10181.

Beshir, A.B., Argueta, C.E., Menikarachchi, L.C., Gascón, J.A., Fenteany, G. Locostatin disrupts association of Raf kinase inhibitor protein with binding proteins by modifying a conserved histidine residue in the ligand-binding pocket. *Forum Immunopath. Dis. Ther.* 2011, 2:47–5

Eddy, N.A., Morse, P.D., Morton, M.D., Fenteany, G. Synthesis of oxazolidinone and tosyl enamines by tertiary amine catalysis. *Synlett* 2011, 5:699–701.

Wang, Z., Castellano, S., Kinderman, S.S., Argueta, C.E., Beshir, A.B., Fenteany, G., Kwon, O. Diversity through a branched reaction pathway: Generation of a library of sixteen multicyclic scaffolds and identification of antimigratory agents. *Chem. Eur. J.* 2011, 17:649–654.

Beshir, A.B., Ren, G., Magpusao, A.N., Barone, L.M., Yeung, K.C., Fenteany, G. Raf kinase inhibitor protein suppresses nuclear factor-κB-dependent cancer cell invasion through negative regulation of matrix metalloproteinase expression. *Cancer Lett.* 2010, 299:137–149.

Kahsai, A.W., Zhu, S., Fenteany, G. G protein-coupled receptor kinase 2 activates radixin, regulating membrane protrusion and motility in epithelial cells. *Biochim. Biophys. Acta* 2010, 1803:300–310.

Knecht, D.A., LaFleur, R., Kahsai, A.W., Argueta, C.E., Beshir, A.B., Fenteany, G. Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics. *PLoS One* 2010, 5:e14039.

Magpusao, A.N., Desmond, R., Billings, K.J., Fenteany, G., Peczuh, M.W. Synthesis and evaluation of antimigratory and antiproliferative activities of lipid-linked [13]-macro-dilactones. *Bioorg. Med. Chem. Lett.* 2010, 20:5472–5476.

Ménoret, A., McAleer, J.P., Ngoi, S.-M., Ray, S., Eddy, N.A., Fenteany, G., Lee, S.-J., Rossi, R.J., Mukherji, B., Allen, D.L., Chakraborty, N.G., Vella, A.T. The oxazolidinone derivative locostatin induces cytokine appeasement. *J. Immunol.* 2009, 183:7489–7496.

Beshir, A.B., Guchhait, S.K., Gascon, J.A., Fenteany, G. Synthesis and structure–activity relationships of metal–ligand complexes that potently inhibit cell migration. *Bioorg. Med. Chem. Lett.* 2008, 18:498–504.

Kahsai, A.W., Cui, J., Kaniskan, H.Ü., Garner, P.P., Fenteany, G. Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site. *J. Biol. Chem.* 2008, 283:24534–24545.

Mc Henry, K.T., Montesano, R., Zhu, S., Beshir, A.B., Tang, H.H., Yeung, K.C., Fenteany, G. Raf kinase inhibitor protein positively regulates cell–substratum adhesion while negatively regulating cell–cell adhesion. *J. Cell. Biochem.* 2008, 103:972–985.

Farooqui, R., Zhu, S., Fenteany, G. Glycogen synthase kinase-3 acts upstream of ADP-ribosylation factor 6 and Rac1 to regulate epithelial cell migration. *Exp. Cell Res.* 2006, 312:1514–1525.

Kahsai, A.W., Zhu, S., Wardrop, D.J., Lane, W.S., Fenteany, G. Quinocarmycin analog DX-52-1 inhibits cell migration and targets radixin, disrupting interactions of radixin with actin and CD44. *Chem. Biol.* 2006, 13:973–983.

Stossel, T.P., Fenteany, G., Hartwig, J.H. Cell surface actin remodeling. *J. Cell Sci.* 2006, 119:3261–3264.

Farooqui, R., Fenteany, G. Multiple rows of cells behind an epithelial wound edge extend cryptic lamellipodia to collectively drive cell-sheet movement. *J. Cell Sci.* 2005, 118:51–63.

Zhu, S., Mc Henry, K.T., Lane, W.S., Fenteany, G. A chemical inhibitor reveals the role of Raf kinase inhibitor protein in cell migration. *Chem. Biol.* 2005, 12:981–991.

Altan, Z.M., Fenteany, G. c-Jun N-terminal kinase regulates lamellipodial protrusion and cell sheet migration during epithelial wound closure by a gene expression-independent mechanism. *Biochem. Biophys. Res. Commun.* 2004, 322:56–67.

Fenteany, G., Glogauer, M. Cytoskeletal remodeling in leukocyte function. *Curr. Opin. Hematol.* 2004, 11:15–24.

Ankala, S.V., Fenteany, G. Aryl, alkyl bis-silyl ethers: Rapid access to monoprotected aryl alkyl and biaryl ethers. *Synlett* 2003, 6:825–828.
Fenteany, G., Zhu, S. Small-molecule inhibitors of actin dynamics and cell motility. *Curr. Topics Med. Chem.* 2003, 3:593–616.
Ankala, S.V., Fenteany, G. Selective deprotection of either aryl or alkyl silyl ethers from aryl, alkyl bis-silyl ethers. *Tetrahedron Lett.* 2002, 43:4729–4732.
Mc Henry, K.T., Ankala, S.V., Ghosh, A.K., Fenteany, G. A non-antibacterial oxazolidinone derivative that inhibits epithelial cell sheet migration. *ChemBioChem* 2002, 3:1105–1111.
Fenteany, G., Janmey, P.A., Stossel, T.P. Signaling pathways and cell mechanics involved in wound closure by epithelial cell sheets. *Curr. Biol.* 2000, 10:831–838.
Corey, E.J., Li, W.Z., Nagamitsu, T., Fenteany, G. The structural requirements for inhibition of proteasome function by the lactacystin-derived β-lactone and synthetic analogs. *Tetrahedron* 1999, 55:3305–3316.
Fenteany, G., Schreiber, S.L. Lactacystin, proteasome function, and cell fate. *J. Biol. Chem.* 1998, 273:8545–8548.
Degnan, B.M., Degnan, S.M., Fenteany, G., Morse, D.E. A Mox homeobox gene in the gastropod mollusc *Haliotis rufescens* is differentially expressed during larval morphogenesis and metamorphosis. *FEBS Lett.* 1997, 411:119–122.
Craiu, A., Gaczynska, M., Akopian, T., Gramm, C.F., Fenteany, G., Goldberg, A.L., Rock, K.L. Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. *J. Biol. Chem.* 1997, 272:13437–13445.
Fenteany, G., Schreiber, S.L. Specific inhibition of the chymotrypsin-like activity of the proteasome induces a bipolar morphology in neuroblastoma cells. *Chem. Biol.* 1996, 3:905–912.
Fenteany, G., Standaert, R.F., Lane, W.S., Choi, S., Corey, E.J., Schreiber, S.L. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. *Science* 1995, 268:726–731.
Fenteany, G., Standaert, R.F., Reichard, G.A., Corey, E.J., Schreiber, S.L. A β-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. *Proc. Natl. Acad. Sci. USA* 1994, 91:3358–3362.
Fenteany, G., Morse, D.E. Specific inhibitors of protein synthesis do not block RNA synthesis or settlement of planktonic larvae in a marine gastropod mollusc (*Haliotis rufescens*). *Biol. Bull.* 1993, 184:6–14.
-lactone related to lactacystin induces neurite outgrowth in a neuroblastoma cell line and inhibits cell cycle progression in an osteosarcoma cell line. *Proc. Natl. Acad. Sci. USA* 1994, 91:3358–3362.
Fenteany, G., Morse, D.E. Specific inhibitors of protein synthesis do not block RNA synthesis or settlement of planktonic larvae in a marine gastropod mollusc (*Haliotis rufescens*). *Biol. Bull.* 1993, 184:6–14.

PATENTS

Compound libraries made through phosphine-catalyzed annulation/Tebbe/Diels-Alder reactions
US 862403: publication date: Jan. 7, 2014; filing date: Nov. 9, 2012; priority date: Nov. 9, 2011; also published as: US20130143916; Inventors: Ohyun Kwon, Gabriel Fenteany

Inhibitors of animal cell motility and growth
US 7390826: publication date: Jun. 24, 2008; filing date: Oct. 26, 2005; priority date: Jun. 12, 2002; also published as US20030236290, US20060063935, WO2003106437A1; Inventors: Gabriel Fenteany, Arun K. Ghosh, Kevin McHenry, Sudha Ankala, Sarosh Anjum, Shoutian Zhu

Lactacystin analogs
US 6645999: PCT number: PCT/US1996/005072; publication date: Nov. 11, 2003; filing date: Apr. 12, 1996; also published as: CA2217817A1, CN1151787C, CN1187769A, DE69636902D1, DE69636902T2, EP0820283A1, EP0820283A4, EP0820283B1, US5756764, US6147223, US6214862, US6335358, US6458825, WO1996032105A1; Inventors: Gabriel Fenteany, Robert F. Standaert, Timothy F. Jamison, Stuart L. Schreiber

AWARDS AND HONORS

2007	University of Connecticut Undergraduate Student Government Educator of the Year Nominee
2002 – 2006	American Cancer Society Research Scholar
1999 – 2000	Life Sciences Research Foundation Postdoctoral Fellowship
1999	National Institutes of Health Postdoctoral Fellowship (Declined)
1999	American Lung Association Postdoctoral Fellowship (Declined)

1991 – 1994	National Defense Science and Engineering Graduate Fellowship
1990	Elections to Phi Beta Kappa and Golden Key National Honor Societies
1985	Alice Tweed Tuohy Honors Scholarship, Scholarship Foundation of Santa Barbara

FORMAL GRANT REVIEWING

2011	National Science Foundation – Division of Chemistry
2009	National Institutes of Health – Synthetic and Biological Chemistry B Study Section, *Ad Hoc* Member
2009	National Science Foundation – Integrative Organismal Systems – Animal Developmental Mechanisms
2009	National Institutes of Health, Stage 1 Reviewer for RC1 Challenge Grants
2008	American Heart Association Bioengineering 2 Peer Review Study Group
2007 – 2008	National Science Foundation – Molecular and Cellular Biosciences
2006	National Institutes of Health – Synthetic and Biological Chemistry B Study Section, *Ad Hoc* Member
2003 – 2006	American Cancer Society
2003	Vahlteich Endowment Research Fund